Two-Year Results of Intravitreal Bevacizumab Injection in Retinal Vein Occlusion.
10.3341/jkos.2011.52.9.1039
- Author:
Young Seob LEE
1
;
Moo Sang KIM
;
Seung Young YU
;
Hyung Woo KWAK
Author Information
1. Department of Ophthalmology, Kyung Hee University School of Medicine, Seoul, Korea. syyu@khu.ac.kr
- Publication Type:Original Article
- Keywords:
Bevacizumab;
Macular edema;
OCT results;
Retinal vein occlusion;
Two-year results
- MeSH:
Antibodies, Monoclonal, Humanized;
Eye;
Follow-Up Studies;
Humans;
Macular Edema;
Retinal Detachment;
Retinal Vein;
Retinal Vein Occlusion;
Retinaldehyde;
Retrospective Studies;
Tomography, Optical Coherence;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2011;52(9):1039-1047
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The authors evaluated the 2-year clinical results of intravitreal bevacizumab injection in retinal vein occlusion (RVO). METHODS: Thirty-two eyes of 32 patients treated with an intravitreal bevacizumab injection of 1.25 mg (0.05 ml) for RVO (branch RVO: 22 eyes, central RVO: 10 eyes), repeated 3 times at a 6-week interval and were available for a follow-up period of at least 2 years were retrospectively reviewed. Best-corrected visual acuity (BCVA) before treatment and 6, 12, and 24 months after 3 serial injections, was recorded. The optical coherence tomography (OCT) results were analyzed to identify prognostic factors for recurrent macular edema that needed reinjection. RESULTS: Two years after the treatment, mean BCVA was significantly improved (p = 0.000). Out of 32 eyes, 16 (branch RVO: 8 eyes; central RVO: 8 eyes) needed reinjection because of recurrent macular edema. In central RVO, a significantly high reinjection rate was shown in serous retinal detachment (SRD) compared with cystoid macular edema (CME) as identified in OCT findings (p = 0.049). Additionally, in branch RVO, a high reinjection rate was shown in SRD, although statistically not significant (p = 0.375). CONCLUSIONS: In patients with RVO, a significant visual improvement was maintained for at least 2 years after intravitreal bevacizumab injection. Based on OCT results, SRD showed a high reinjection rate compared with CME in CRVO.
